Skip to main content

Navigation group

Volumes

107 Publications

Volume 3 - 2024

Original Research

Published on 11 Sep 2024

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

  • Amalia Domingo-González
  • Rafael Alonso Fernández
  • Ana Jiménez
  • Teresa De Soto Álvarez
  • Ana Lerma-Verdejo
  • Virginia Pradillo
  • Gonzalo Benzo Callejo
  • Jose Sánchez-Pina
  • Elena Landete
  • Alberto Velasco-Valdazo
Frontiers in Hematology
doi 10.3389/frhem.2024.1438233
  • 381 views

Study Protocol

Accepted on 20 Aug 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

  • Theo Leitner
  • Evgenii Shumilov
  • Christina Schwitlick
  • Raphael Koch
  • Franziska Hamm
  • Marion Högner
  • Florian Bassermann
  • Katja Weisel
  • Hermann Einsele
  • Leo Rasche
Frontiers in Hematology
doi 10.3389/frhem.2024.1436845
  • 119 views